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httpcense.Abstract Objectives: To assess the value of PCT as a rapid and sensitive marker for diagnosis,
prognosis, and therapy of lower respiratory tract bacterial infections necessitating antimicrobial
treatment and comparing this marker with other markers of infections including C-reactive protein
(CRP) and total white-blood cell counts (WBCs).
Patients and methods: Sixty Patients were enrolled in the study, they were subjected to complete
history taking, physical examination, laboratory investigations including complete blood count,
blood gases, blood chemistry, bacteriological culture for sputum and blood, serology for atypicals,
and PCR for respiratory viruses, serum C-reactive protein (CRP) and PCT levels were measured.
The patients were divided into two groups, group 1 included 26 patients who were culture negative
for bacterial infection and group 2 included 34 patients who were culture positive. Group 2 patients
were given antibiotic therapy according to the culture sensitivity.
Result: The results revealed that, there was no signiﬁcant difference between group 1 and group
2 patients as regards age, sex, clinical manifestations, ﬁnal diagnosis, white blood cell counts, blood
gases, number of admitted patients, intensive care unit admission and length of hospital stay. A sig-
niﬁcant increase of PCT and CRP levels was detected in group 2 compared to group 1 at initial00089246.
(A.A. El-Azeem).
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688 A.A. El-Azeem et al.diagnosis. At cutoff value >0.5 ng/ml, PCT gave a sensitivity of 94.1%, speciﬁcity of 88.4%, posi-
tive predictive value (PPV) of 91.4%, negative predictive value (NPV) of 92% and diagnostic efﬁ-
ciency of 91.6% for diagnosis of respiratory tract bacterial infections. However, at a cutoff value
>8 mg/L, CRP gave a sensitivity of 85.2%, speciﬁcity of 76.9%, PPV of 82.8%, NPV of 80%
and diagnostic efﬁciency of 81.7%. After antibiotic therapy PCT and CRP levels dropped in group
2 patients as compared to their pre-treatment levels.
Conclusion: Serum PCT level could be used as a novel marker of lower respiratory tract bacterial
infections for diagnosis, prognosis and follow up of therapy. This reduces side-effects of an unnec-
essary antibiotic use, lowers costs, and in the long-term, leads to diminishing drug resistance.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.Introduction
Acute respiratory infections (ARIs) comprise a large and heter-
ogeneous group of infections, including bacterial infections, vir-
al infections, and infections of other etiologies. Early initiation
of adequate antibiotic therapy is the cornerstone in the treat-
ment of bacterial ARIs and is associated with improved clinical
outcomes [1]. However, overuse of antibiotics by over-prescrip-
tion in outpatients and prolonged duration of antibiotic therapy
in patients with bacterial ARIs in the hospital and intensive care
setting is associated with increased resistance for common bac-
teria, high costs, and adverse drug reactions [2]. A novel ap-
proach to estimate the likelihood of bacterial infections and
the severity of disease is the use of blood biomarkers mirroring
the host response to infection, and the severity of infection. In
recent years, procalcitonin (PCT) has emerged as a promising
marker for the diagnosis of bacterial infections because higher
levels are found in severe bacterial infections than in viral infec-
tions and nonspeciﬁc inﬂammatory diseases. Hence, PCT may
be used to support clinical decision making for the initiation
and discontinuation of antibiotic therapy [3].
Procalcitonin is a prohormone of the calcium homeostasis
hormone calcitonin. In non-infectious conditions it is pro-
duced in the neuroendocrine medullary C-cells of the thyroid
gland. In normal subjects circulating procalcitonin concentra-
tions are low (<0.05 ng/mL), but bacterial infections selec-
tively induce an increase in the concentration of
procalcitonin (in parenchymal tissues) because both endotox-
ins (lipopolysaccharides) from the bacterial cell wall and host
responses to infection stimulate the production of procalcito-
nin by cytokines, such as IL-1 b, tumor necrosis factor-a,
and IL-6. The up-regulation of PCT correlates with the sever-
ity and extent of bacterial infections. This results in an accu-
mulation of procalcitonin because, unlike neuroendocrine
cells, parenchymal cells lack the ability to cleave procalcitonin
into its mature form, calcitonin [4]. Conversely, interferon-c, a
cytokine released in response to viral infections, blocks the up-
regulation of PCT, resulting in a higher speciﬁcity of PCT to-
ward bacterial infections. Quantitatively, PCT may help distin-
guish severe bacterial infections from milder viral illnesses [5].
It is detectable within 2–4 h and peaks within 6–24 h (as op-
posed to CRP which begins to rise after 12–24 h and peaks
at 48 h) [6]. PCT production is not impaired by neutropenia
or other immunosuppressive states. PCT levels parallel the
severity of the inﬂammatory insult or infections meaning those
with more severe disease have higher levels [7]. Furthermore,procalcitonin has some utility as a prognostic indicator with
higher serum concentrations related to the risk of mortality [8].
PCT has some advantages over other biomarkers in com-
mon clinical use such as C-reactive protein (CRP) and white
blood cell count. These advantages include speciﬁcity for bac-
terial infection, the rapidity of its rise after an insult (6 h), the
rapid decline with immune control on infection (half-life of
24 h), excellent correlation with severity of illness (higher levels
in more severely ill), and the lack of impact of anti-inﬂamma-
tory and immunosuppressive states on production [9]. PCT
was used as a guide in the following situations:
 Differentiation of bacterial verses viral respiratory tract
infection.
 Determination of the duration of antibiotic treatment in
respiratory infections.
 Diagnosis and monitoring of sepsis and septic shock.
 Prognostic usefulness in classifying the patients as low risk
or high risk for bacterial infection and/or sepsis and predic-
tion of mortality.
 Monitoring the response to antibacterial therapy.
 Differentiating bacterial verses viral meningitis.
 Diagnosis of bacterial infection in neutropenic patients [10].
Decisions regarding antimicrobial therapy should NOT be based
solely on procalcitonin serum concentrations
Procalcitonin should be placed into the clinical context of each
patient scenario considering the site of possible infection, the
likelihood of bacterial infection, and the severity of illness [11].
Most studies on sepsis have evaluated using PCT to initiate
or discontinue antibiotics so, the decision to initiate therapy in
the ICU should be driven by the severity of illness and clinical
assessment of the likelihood of infection and PCT was used as
a guide to assist when to initiate or stop antibiotics. PCT levels
that are not declining or are increasing are strong prognostic
indicators of lack of control on the infection by the host im-
mune system and/or antibiotics. It has been recommended
that further diagnostic procedures/imaging or broader
spectrum antibiotics should be initiated based upon this rising
value [12].
A recent study used PCT values of >1 lg/L as an ‘‘alert’’ to
suggest broadening of therapy and further imaging. This high
value can also give prognosis of an increased length of stay in
the ICU and on the ventilator. In these situations, it is
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other sites/sources of infection or evidence of resistant patho-
gens and decisions regarding further interventions to be made
based upon this evaluation [13].
Aim of the work
The aim of this review, was focusing on respiratory infec-
tions to give a potential usefulness on PCT as a guide in
diagnosing bacterial infections, differentiating bacterial from
viral diseases, prognosticating the severity of a patient’s
condition, and guiding clinical decisions about when to
initiate antibiotic therapy and when it can be safely
discontinued.
Patients and methods
A total number of 60 patients (28 males, 32 females) were in-
cluded in the study from December 2011 to January 2013; they
were randomly selected from outpatient clinic and inpatient
departments of Al Sabah Hospitals in Kuwait.
Inclusion criteria
Any patient presenting with fever, cough, expectoration and/
or dyspnea and suspected to have lower respiratory tract infec-
tion as the main diagnosis including pneumonia, acute exacer-
bation of asthma, COPD and acute bronchitis was included.
The patients were subjected to the following
(1) Detailed history and physical examination.
(2) Chest radiography was done to all patients.
(3) Sputum and blood were collected for bacterial culture by
using speciﬁc media for each organism. Microorganisms
were recorded if they were detected in sputum, blood
cultures, or both.
(4) Fresh heparinized arterial blood samples were collected
for blood gases’ analysis, on room air (on AVL-autoan-
lyzer-Roche).
(5) Serology for atypicals including Chlamydia pneumonia
IgA/IgM/IgG, Coxiella bruntii IgM/IgG, legionella
pneumonia IgM/IgG, Mycoplasma pneumonia IgA/
IgM/IgG, using (Enzyme Linked Immunosorbent
Assay) ELISA which is an immunoassay, suited to the
determination of antibodies in the ﬁeld of infectious
serology. The reaction is based on the speciﬁc interac-
tion of antibodies with their corresponding antigen.
Therefore, the test strips of the SERION ELISA classic
micro-titer plate are coated with speciﬁc antigens of the
pathogen of interest. If antibodies in the patient´s serum
sample are present, they bind to the ﬁxed antigen. A sec-
ondary antibody, which has been conjugated with the
enzyme alkaline phosphatase, detects the immune com-
plex. The colorless substrate p-nitrophenylphosphate is
then converted into the colored product p-nitro phenol.
The signal intensity of the reaction product is propor-
tional to the concentration of the analyte in the sample
and is measured photometrically.
(6) Urine test for Legionella antigen.(7) Sputum or nasopharyngeal swab for PCR to detect
respiratory viruses included, Inﬂuenza A/B IgA/IgM/
IgG, Para-inﬂuenza virus 1, 2, 3 IgA/IgG, Herpes sim-
plex virus 1/2 IgA/IgM/IgG, Cytomegalovirus IgM/
IgG, Epstein – Barr virus IgG/IgM,Herpes Simplex
Virus 1/2 IgM/IgG. Pathogen detection by the polymer-
ase chain reaction (PCR) is based on the ampliﬁcation of
speciﬁc regions of pathogen genome. In real time PCR
the ampliﬁed product is detected via ﬂorescent dyes.
These are linked to oligonucleotide probes that bind spe-
ciﬁcally to the ampliﬁed product. Monitoring the ﬂuo-
rescence intensities during the PCR run (i.e. real-time)
allows the detection and quantiﬁcation of the accumu-
lating product without having to re-open the reaction
tubes after the PCR run. The ARTUS SARS RG RT-
PCR kit was used to detect the novel coronal virus.
The artus SARS RG RT-PCR Kit is based on the ampli-
ﬁcation and simultaneous detection of a speciﬁc region
of the SARS corona virus genome using real-time
PCR. The kit provides high levels of speciﬁcity, sensitiv-
ity, and reproducibility. Each artus SARS RG RT-PCR
Kit provides 4 quantitation standards. The use of stan-
dards enables accurate quantitation of viral load. In
addition, the kit contains a second heterologous ampliﬁ-
cation system to identify possible PCR inhibition. This is
detected as an internal control (IC) in a different ﬂuores-
cence channel from the analytical PCR. The detection
limit of the analytical SARS corona virus RT-PCR is
not reduced.
(8) Venous blood samples were collected from patients in 2
tubes, 2 ml of blood was delivered into EDTA tube to
perform complete blood picture on the automatic cell
counter.
(9) The remaining amounts of blood were coagulated then
centrifuged at 4000 rpm for 10 min, one part of the sep-
arated serum was used to assay blood chemistry (on Hit-
achi 911-Roche) and CRP concentration (on Axyem,
Bayer-Germany), a value of CRP > 8 mg/L was consid-
ered abnormally elevated [14].
(10) The second part of the serum was stored in aliquots at
70 C for measurements of PCT until time of assay.
Serum PCT measurement was done using a luminescence
immunoassay (LIA) for speciﬁc measurement of PCT in serum
by using Elecyes 1020. In LIA, PCT covalently bound to para-
magnetic particles for limited binding sites on acridine ester-la-
beled antibody. An inverse relationship exists between the
concentrations of labeled antibody bound to the antigen
PCT in the patient sample. This triggers the chemiluminescent
reaction that results in the emission of photons of light. The
photo multiplier tube detects the photon of light emitted and
converts them into electrical pulses. The instrument counts
these electrical pulses, reads the results off the master curve de-
ﬁned for the assay. The results were calculated from the stan-
dard curve in ng/ml. The detection limit of the assay was
0.1 ng/mL [15].
Patients were divided into two groups
Group 1: included 26 patients (12 males and 14 females), they
were bacteriologically culture negative.
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were bacteriologically culture positive, and were given antibi-
otic therapy according to the antibiotic sensitivity test.
Interpretation of procalcitonin levels
Normal: <0.1 ng/mL (infants >72 h – adults).
Suspected lower respiratory tract infection
 0.1–0.25 ng/mL – Low likelihood for bacterial infection;
antibiotics discouraged.
 >0.25 ng/mL – Increased likelihood for bacterial infection;
antibiotics encouraged [16].
Suspected sepsis: Strongly consider initiating antibiotics in
all unstable patients.
 0.1–0.5 ng/mL – Low likelihood for sepsis.
 >0.5 ng/mL – Increased likelihood for sepsis.
 >2.0 ng/mL – High risk of sepsis.
 >10 ng/mL – Septic shock [17].
Higher PCT levels have been associated with a worse prog-
nosis [5]. If antibiotics are administered, repeat procalcitonin
testing every 2–3 days to consider early antibiotic cessation
as shown in algorithm1 and 2 (Fig. 1).
Limitations of procalcitonin: False positive and false nega-
tive results can occur and the clinical context should guide
interpretation of PCT results.
A false positive result, situations where the PCT elevations may
be due to a non-bacterial causes [18]
 Newborns (<48–72 h; after 72 interpret levels as usual).
 Massive stress (severe trauma, surgery, cardiac shock,
burns).Table 1 Characteristics of both patients groups.
Variables Group 1 (N= 26)
Age (mean ± SD) 53.2 ± 9.3
Men/women 12/14
Body temperature (C)(mean ± SD) 38.9 ± 1Æ2
Symptoms No. (%)
Cough 24 (92.3%)
Sputum (yellow or green) 12 (46.2)%
Dyspnea 16 (61.5%)
Signs:
Rales 13 (50%)
Wheezing 11 (42.3%)
Chest radiograph inﬁltrate 9 (34.6%)
Final diagnosis No. (%)
Acute bronchitis 8 (30.7%)
Acute exacerbation of asthma 2 (7.7%)
Pneumonia 10 (38.4%)
Acute exacerbation of COPD 6 (23.1%) Treatment with agents which stimulate cytokines (anti-lym-
phocyte globulins, alemtuzumab, IL-2, granulocyte
transfusion).
 Malaria and some fungal infections.
 Prolonged, severe cardiogenic shock or organ perfusion
abnormalities.
 Some forms of vasculitis and acute graft vs. host disease.
 Paraneoplastic syndromes due to medullary thyroid and
small cell lung cancer.
False negative results
(1) PCT levels may not rise with localized infections as
parapneumonic effusion, loculated infection (empyema),
(osteomyelitis, localized abscess, etc.) [19].
(2) If the sample is taken for PCT measurement early in the
course of infection [20].
(3) If the patient is taking steroids as they can inhibit the
pathway for PCT production. This is important in
patients with chronic lung conditions such as COPD,
asthma or pulmonary ﬁbrosis [19].
Result
The patients characteristics revealed that, no signiﬁcant differ-
ence was detected between group 1 (culture negative group)
and group 2 patients (culture positive group) as regards age,
sex, symptoms, signs, body temperature and ﬁnal diagnosis
(Table 1).
Table 2 shows a signiﬁcant increase in CRP levels and a
highly signiﬁcant increase in PCT levels in group 2 as com-
pared to group 1 at initial diagnosis. No signiﬁcant difference
as regards white blood cell counts or blood gases was detected.
Also no signiﬁcant difference was detected as regards number
of admitted patients, intensive care unit admission or admittedGroup 2 (N= 34) t-Test P value
48.2 ± 6.4 0.83 >0.05
16/18 >0.05
39.1 ± 1Æ1 0.25 >0.05
No. (%) v2
30 (88.2%) 1.31 >0.05
16 (47.1%) 0.07 >0.05
23 (67.6%) 1.92 >0.05
18 (52.9%) 0.67 >0.05
15 (44.1%) 0.32 >0.05
13 (38.2%) 1.04 >0.05
No. (%) v2
13 (38.2%) 2.01 >0.05
0 (0.0%) 2.89 >0.05
11 (32.4%) 1.06 >0.05
10 (29.4%) 0.72 >0.05
Table 2 Some laboratory variables in patients with lower respiratory tract infection.
Variable At Initial diagnosis
Group1(n= 26) Mean ± SD Group 2 (n= 34) Mean ± SD Test value t p
White blood cell (·106/L) 19.9 ± 4.9 22.6 ± 7.8 0.39 >0.05
CRP (mg/L) 15.9 ± 6.8 44.8 ± 26.2 0.36 <0.05*
Procalcitonin (ng/mL) 1.2 ± 0.9 4.8 ± 3.9 8.05 <0.001**
Blood gases
Pa O2 (mm Hg) 86.9 ± 8.5 83.7 ± 9.4 0.61 >0.05
Pa CO2 (mm Hg) 41.7 ± 8.8 42.8 ± 9.0 0.73 >0.05
pH 7.3 ± 0.01 7.4 ± 0.02 0.08 >0.05
* P value is signiﬁcant at < 0.05.
** P value highly signiﬁcant at < 0.001.
Table 3 Hospital data of patients with lower respiratory tract infection.
Variable Group 1 (n= 26) Group 2 (n= 34) v2 P value
Admitted patients 15 (57.7%) 14 (41.2%) 0.08 >0.05
Intensive care unit admission 1 (3.8%) 1 (2.9%) 0.96 >0.05
Length of hospital stay Mean ± SD 8.4 ± 3.1 Mean ± SD 10.5 ± 5.1 P value >0.05
Table 4 Organisms isolated in group 2 patients (positive culture) before treatment.
Variables Sputum (+ve) only Blood culture (+ve) only Both (+ve)
Pneumonia (n= 11) No.% 5 (45.4%) 4 (36.4%) 2 (18.1%)
S. pneumoniae 3 (27.3%) 3 (27.3%) 1 (9.1%)
M. catarrhalis 1 (9.1%) – 1 (9.1%)
Pseudomonas spp 1 (9.1%) 1(9.1%) –
COPD (n= 10) No.% 4 (40%) 3 (30%) 3 (30%)
S. pneumoniae 2 (20%) 2 (20%) 2 (20%)
H. inﬂuenzae 1 (10%) – –
S. aureus 1(10%) 1 (10%) 1(10%)
Pseudomonas spp. - 1(10%) –
Bronchitis (n= 13) No.% 8 (61.5%) 4 (30.7%) 1 (7.6%)
S. pneumoniae 3 (23%) 2(15.4%) 1(7.6%)
S. aureus 2 (15.4%) 1(7.6%) –
Pseudomonas spp. 2(15.4%) 1(7.6%) –
M. catarrhalis 1(7.6%) – –
Table 5 Sensitivity, Speciﬁcity, PPV and NPV of serum
procalcitonin and C- reactive protein for the diagnosis of
respiratory tract infection.
PCT (ng/ml) CRP (mg/L)
Cutoﬀ value >0.5 >8
Sensitivity 94.1% 85.2%
Speciﬁcity 88.4% 76.9%
PPV 91.4% 82.8%
NPV 92% 80%
Diagnostic eﬃciency 91.6% 81.7%
PCT: procalcitonin CRP: C-reactive protein PPV: positive predic-
tive value NPV: negative predictive value.
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Table 3.
Table 4 shows the number and the percentage of bacterial
organisms that had been isolated from group 2 patients. In11 patients with pneumonia, the Streptococcus pneumoniae,
Morexella catarrhalis and Pseudomonas spp. were isolated.
These bacteria were isolated from sputum of 5 cases
(45.4%), from blood of 4 cases (36.4%) and from both of 2
cases (18.1%). In 10 patients with COPD, S. pneumoniae,
Hemophilus inﬂuenza, Staphylococcus aureus and P. spp. were
isolated. These bacteria were isolated from sputum of 4 cases
(40%), from blood of 3 cases (30%) and from both of 3 cases
(30%) while, S. pneumoiae, S. aureus, Pseudomonas spp. and
M. catarrhalis were isolated from the 13 patients with bronchi-
tis. These bacteria were isolated from sputum of 8 cases
(61.5%), from blood of 4 cases (30.7%) and from both of
one case (7.6%). Both blood and sputum cultures were nega-
tive in all cases that had acute exacerbation of asthma.
Table 5 demonstrates the value of PCT and CRP in diagno-
sis of the lower respiratory tract bacterial infection, at a cutoff
value >0.5 ng/ml, PCT gave a sensitivity of 94.1%, speciﬁcity
of 88.4%, positive predictive value (PPV) of 91.4%, negative
predictive value (NPV) of 92% and diagnostic efﬁciency of
Table 6 Comparison between laboratory tests before and after therapy in group 2 patients.
Variable Group 2 patients after antibiotic therapy
Before treatment Mean ± SD After treatment Mean ± SD Test value t p
White blood cell counts (·106/L) 22.6 ± 8.8 11.8 ± 6.9 3.59 <0.05
C-reactive protein (mg/L) 49.8 ± 28.2 9.5 ± 4.3 4.36 <0.001
Procalcitonin (ng/mL) 4.8 ± 3.9 0.8 ± 0.65 6.57 <0.001
Algorithm 1: LRTI Initial PCT Value 
PCT Value 
Antibiotic Use 
Recommendation
<0.1 μg/L 0.1-0.24 μg/L ≥0.25-0.5 μg/L >0.5 μg/L
Strongly
Discouraged Discouraged Encouraged
Strongly
Encouraged
• Consider alternative diagnosis. 
• Repeat PCT in 6-12 hours if antibiotics
not begun and no clinical improvement. 
• If clinically unstable, immunosuppressed
or high risk consider overruling (PSI
Class IV-V, CURB > 2, GOLD III or IV).
Repeat every 2-3 days to 
consider early antibiotic 
cessation
See Algorithm 2
Algorithm 2: LRTI PCT Value Follow Up 
PCT Value 
Antibiotic Use 
Recommendation
<0.1 μg/L or 
drop by > 90%
0.1-0.24 μg/L or
drop by >80% 
≥0.25-0.5 μg/L >0.5 μg/L
Cessation
Strongly
Encouraged 
Cessation
Encouraged
Cessation
Discouraged
Cessation
Strongly
Discouraged
Consider continuing if 
clinically unstable 
If PCT rising or not adequately 
decreasing consider possible 
treatment failure and evaluate 
for need for expanding 
antibiotic coverage or further 
diagnostic evaluation 
Figure 1 The use of PCT in the initiation and cessation of antibiotics [21].
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ity of 85.2%, speciﬁcity of 76.9%, PPV of 82.8%, NPV of 80%
and diagnostic efﬁciency of 81.7%.
Table 6 shows a highly signiﬁcant decrease in PCT and
CRP levels in group 2 patients after antibiotic therapy. Also
the white blood cell counts were signiﬁcantly decreased as
compared to pretreatment levels.
Statistical analysis
A statistical analysis of data was done using SPSS computer
program version 12. A comparison between two parametric
quantitative variables was done using student’s (t) test. Chi
square (v2) was used to compare between qualitative variables.
P value < 0.05 was considered statistically signiﬁcant and that
>0.05 was considered insigniﬁcant. Sensitivity, speciﬁcity, po-
sitive predictive value (PPV), negative predictive value (NPV)
and diagnostic efﬁciency were calculated.Discussion
Identifying a true ‘‘gold standard’’ for the diagnosis of respira-
tory infections is often problematic. The use of blood and spu-
tum cultures has signiﬁcant limitations because of the duration
of time required to obtain positive cultures and issues of colo-
nization and contamination in addition to, the inability to
grow certain bacteria in standard cultures [22].
In this study we evaluated the value of PCT as a rapid and
sensitive marker for diagnosis of bacterial lower respiratory
tract infections needing antimicrobial treatment and its value
in the prognosis and follow up of therapy. We also assessed
the value of procalcitonin (PCT) compared with other markers
of infections including C-reactive protein (CRP) and total
white-blood cell counts (WBCs) in predicting bacterial lower
respiratory tract infections. The current study revealed that,
there was no signiﬁcant difference between bacterial culture
negative group and culture positive group as regards age,
The role of procalcitonin as a guide for the diagnosis, prognosis, and decision of antibiotic therapy 693sex, clinical manifestations, blood gases, number of admitted
patients, intensive care unit admission or admitted days be-
tween both groups of patients. This may hinder the diagnosis
and proper therapeutic interference.
Our data regarding the clinical diagnosis showed no statis-
tical signiﬁcant difference between culture positive and culture
negative groups. This can be explained by the presence of dif-
ferent etiological factors causing respiratory tract infections.
The culture used in this study was to detect bacterial infections
only, so in culture negative cases, the infection may be due to
other causes including viruses.
COPD and bronchial asthma exacerbation have been asso-
ciated with a number of etiological factors which may be infec-
tious or non infectious. Viral infections are important triggers
for their exacerbations in up to 30% in the former and a higher
percentage in the latter [23]. Controversy exists regarding the
need of antimicrobial agents in acute exacerbation of COPD.Low acuity patients 
(Upper respiratory infection, bronchitis, primary c
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Figure 2 The usefulness of PCT in the diagnosis of bacterialOur ﬁndings are in agreement with those of Sethi and Murphy
who found that, only a quarter of patients with acute exacer-
bations of COPD are estimated to beneﬁt from the addition
of antibiotics to treatment [24].
Our results demonstrate that both PCT and CRP have a
superior discriminatory power to total WBCs in detecting bac-
terial lower respiratory tract infection. Total WBCs were ele-
vated in both groups with no statistically signiﬁcant difference.
CRP is an acute phase protein which has a plasma half-life
that is constant under almost all conditions. CRP has been
widely used clinically as a diagnostic tool for infection identi-
ﬁcation [25].
In the current study CRP was a good marker of bacterial
lower respiratory tract infection. Its level was signiﬁcantly in-
creased in group 2 (culture positive patients) more than in
group 1 (culture negative patients). Both white blood cell
count and CRP are considered to be non-speciﬁc inﬂammatoryμ
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infection, prognosis of severity and antibiotic therapy [5].
694 A.A. El-Azeem et al.parameters with changing reliability, denoting that, both may
be not enough to diagnose the bacterial infection [26]. In our
study after antibiotic therapy, PCT level was dropped in group
2 patients compared to their pre-treatment level.
In one study, Mu¨ller et al., evaluated PCT in a number of
patients with community-acquired pneumonia (CAP) with typ-
ical pathogens, mostly Streptococcus pneumoniae. PCT was
increased signiﬁcantly in bacteremic patients compared with
patients without an identiﬁed bacterial pathogen [27]. Another
study focused on the potential of PCT to differentiate patients
with a viral respiratory infection with or without bacterial
super infection. This was investigated in patients with con-
ﬁrmed inﬂuenza A (H1N1) pneumonia in a critical care setting.
PCT had differentiated the patients with bacterial super-infec-
tion from patients with viral pneumonia only [28]. Different
studies have evaluated the prognostic potential of PCT in pa-
tients with respiratory infections, mainly in patients with CAP,
the greatest beneﬁt of PCT was found in patients classiﬁed as
high risk by the pneumonia severity index score. Having a
PCT < 0.1 ng/ml can exclude mortality in high-risk patients.
Subsequent repeated measurements of PCT in this population
demonstrated improved clinical outcomes with falling PCT
levels [29]. In addition, the study found that PCT was more
helpful in predicting serious adverse events, such as ICU
admission or CAP-related complications [30].
Based on these studies, the prognostic usefulness of PCT in
patients with respiratory infections may be summarized as fol-
lows [5]:
(1) In low-risk patients with respiratory infections, PCT lev-
els <0.25 ng/ml identify patients at lower risk of a bac-
terial cause and CAP and thus low mortality.
(2) In low-risk patients with respiratory infections, PCT lev-
els >0.25 ng/ml identify patients at higher risk of a bac-
terial cause and CAP and, perhaps, higher mortality.
(3) In a high-risk population, PCT levels <0.1 ng/ml effec-
tively decrease the likelihood of mortality from a bacte-
rial cause, and other nonbacterial pathologies should be
aggressively considered.
A number of protocols using PCT measurements can now
be recommended (Fig 2) [5].
(1) In patients with a low probability for a bacterial infection
(e.g., patient with suspected non-pneumonic respiratory
infection), a single PCT measurement and a cutoff of
<0.25 ng/ml or certainly <0.1 ng/ml can exclude bacte-
rial infection and there is no need to initiate an antibiotic
therapy (Fig. 2A). Clinical follow-up with re-measure-
ment of PCT within 6–24 h should be considered in all
patients in whom antibiotics are withheld but who show
clinical deterioration. If PCT is >0.25 ng/ml, and partic-
ularly >0.5 ng/ml, a bacterial infection becomes more
likely and necessitates antibiotic therapy.
(2) For patients who are clinically stable but presented with
pneumonia, a PCT level >0.25 ng/ml strongly suggests
that a bacterial infection and antibiotic therapy should
be initiated, PCT should be reassessed every 2 days.
Antibiotics may be discontinued if a patient shows clin-
ical recovery and PCT decreases to <0.25 ng/ml (or by
at least 80% to 90% from the peak level). Highly ele-vated PCT levels in this situation make bacteremic dis-
ease more likely and suggest that the infection may be
more severe than expected based on clinical signs and
symptoms. In patients suspected of having a pneumonia
based on the presence of radiological inﬁltrates, a persis-
tent (>24–48 h) PCT level of <0.1 ng/ml or even
0.1 ng/ml to <0.25 ng/ml argues against a typical bacte-
rial infection, and physicians should consider the unu-
sual pneumonias as pulmonary embolism, acute heart
failure, bronchiolitis obliterans organizing pneumonia,
Pneumocystis jiroveci pneumonia, and viral pneumonia
particularly during ﬂu season. If antibiotics are withheld
initially, PCT should be rechecked after 6 to 24 h. If
PCT levels are <0.25 ng/ml but bacterial infection is
still highly suspected based on the clinical presentation
or microbiologic results, antibiotic therapy should be
considered. If PCT remains low during follow-up, early
discontinuation of antibiotics should be considered, as
well as an aggressive diagnostic workup for other causes.
(3) For high-risk or patients in the ICU with severe respira-
tory infection (Fig 2B), empiric antibiotic therapy
should be initiated. Still, an initial PCT level of
<0.5 ng/ml argues against a typical bacterial infection,
and other diagnoses should be considered, including
viral causes, repeating the PCT level at 6–24 h in high-
risk patients may be important so as not to miss the evo-
lution of the inﬂammatory cascade, similar to the strat-
egy used for serial troponins in monitoring cardiac
ischemia. If PCT levels do not decrease or remaining
high, treatment failure should be considered and reas-
sessment of patients is recommended.
Conclusion
(1) PCT is not a stand-alone test and will not replace clinical
evaluations of patients. PCT needs to be interpreted in
consideration of the clinical setting.
(2) PCT mirrors the patient’s response to infection and
thus, the extent and severity of infection.
(3) PCT can rule out bacterial infection and provide infor-
mation about patient recovery.
(4) PCT proved as a good diagnostic, prognostic and follow
up of therapy.
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